The need for additional maneuvers was associated with higher rates of neonatal injury. (Obstet Gynecol 2011;117:1272-8) DOI: 10.1097/AOG.0b013e31821a12c9″
“Background: Disturbances in the myocardial extracellular volume fraction (ECV), such as diffuse or focal myocardial fibrosis or edema, are hallmarks of heart disease. Diffuse ECV changes are difficult to assess or quantify with cardiovascular magnetic resonance (CMR) using conventional NVP-HSP990 clinical trial late gadolinium enhancement (LGE), or pre- or post-contrast T1-mapping alone. ECV measurement circumvents
factors that confound T1-weighted images or T1-maps, and has been shown to correlate well with diffuse myocardial fibrosis. The goal of this study was to develop and evaluate an automated
method for producing a pixel-wise map of ECV that would be adequately robust for clinical work flow.
Methods: ECV maps were automatically generated from T1-maps acquired pre- and post-contrast calibrated by blood hematocrit. The JNJ-26481585 mw algorithm incorporates correction of respiratory motion that occurs due to insufficient breath-holding and due to misregistration between breath-holds, as well as automated identification of the blood pool. Images were visually scored on a 5-point scale from non-diagnostic (1) to excellent (5).
Results: The quality score of ECV maps was 4.23 +/- 0.83 (m +/- SD), scored for n = 600 maps from 338 patients with 83% either excellent or good. Co-registration of the pre- and post-contrast images improved the image quality for ECV maps in 81% of the cases. ECV of normal myocardium was 25.4 +/- 2.5% (m +/- SD) using motion correction and co-registration values and was 31.5 +/- 8.7% without motion correction and co-registration.
Conclusions: Fully automated motion correction and co-registration of breath-holds significantly improve the quality of ECV maps, thus making the generation of ECV-maps feasible for clinical work PF-04929113 flow.”
“Background: This study was conducted to evaluate the therapeutic efficacy of a device designed to deliver high-frequency vibratory stimulation through direct intravaginal tampon application (VIPON) compared with a low-dose over-the-counter pharmacologic
treatment of dysmenorrhea.
Methods: A randomized, open-label, prospective study comparing the investigational device to an oral self-administration of the over-the-counter dose of 200-400 mg of ibuprofen with the onset of menstrual discomfort was conducted at two academic medical centers in the Midwest region of the United States. Women age 18 and older with self-reported dysmenorrhea were treated with either VIPON or a single dose of 200-400 mg of ibuprofen, randomized for each of the next four menstrual cycles, and pain reduction from baseline was measured according to the Melzack-McGill pain scale.
Results: Overall, both ibuprofen and VIPON have significant effects on pain reduction according to the Melzack-McGill pain scale.